A human fatty acid synthase inhibitor binds β-ketoacyl reductase in the keto-substrate site

Nature Chemical Biology

Volumn 10, Issue 9, 2014, Pages 774-779

  Hardwicke, Mary Ann ^a   Rendina, Alan R ^a   Williams, Shawn P ^a   Moore, Michael L ^a   Wang, Liping ^a   Krueger, Julie A ^a   Plant, Ramona N ^a   Totoritis, Rachel D ^a   Zhang, Guofeng ^a   Briand, Jacques ^a   Burkhart, William A ^a   Brown, Kristin K ^a   Parrish, Cynthia A ^a  

^a GLAXOSMITHKLINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

3 OXOACYL REDUCTASE; ACETYL COENZYME A ACETYLTRANSFERASE; BETA HYDROXYBUTYRYL COENZYME A ACETYLTRANSFERASE; CROTONYL COENZYME A ACETYLTRANSFERASE; FATTY ACID SYNTHASE; FATTY ACID SYNTHASE INHIBITOR; GSK 2194069; OXIDOREDUCTASE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE; UNCLASSIFIED DRUG;

ARTICLE; CANCER INHIBITION; CANCER SURVIVAL; COMPLEX FORMATION; CRYSTAL STRUCTURE; DISEASE FREE SURVIVAL; DRUG SYNTHESIS; ENZYME ACTIVITY; ENZYME INHIBITION; FATTY ACID SYNTHESIS; GEL PERMEATION CHROMATOGRAPHY; HUMAN; HUMAN CELL; HYDROGEN BOND; HYDROLYSIS; IC 50; LIQUID CHROMATOGRAPHY; LUNG CANCER CELL LINE; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PRIORITY JOURNAL; PROTEIN DOMAIN; TANDEM MASS SPECTROMETRY; WESTERN BLOTTING; X RAY CRYSTALLOGRAPHY;

3-OXOACYL-(ACYL-CARRIER-PROTEIN) REDUCTASE; CATALYTIC DOMAIN; CELL LINE, TUMOR; ENZYME INHIBITORS; FATTY ACID SYNTHASES; HUMANS; MODELS, MOLECULAR; PROTEIN CONFORMATION; PYRROLIDINES; TRIAZOLES; X-RAY DIFFRACTION;

EID: 84906318897     PISSN: 15524450     EISSN: 15524469     Source Type: Journal    
DOI: 10.1038/nchembio.1603     Document Type: Article

References (46)

1. Menendez, J.A. & Lupu, R. Fatty acid synthase and the lipogenic phenotype in cancer pathogenesis. Nat. Rev. Cancer 7, 763-777 (2007).
2. Maier, T., Jenni, S. & Ban, N. Architecture of mammalian fatty acid synthase at 4.5 A resolution. Science 311, 1258-1262 (2006).
3. Chirala, S.S. & Wakil, S.J. Structure and function of animal fatty acid synthase. Lipids 39, 1045-1053 (2004).
4. Asturias, F.J. et al. Structure and molecular organization of mammalian fatty acid synthase. Nat. Struct. Mol. Biol. 12, 225-232 (2005).
5. Hiltunen, J.K. et al. Mitochondrial fatty acid synthesis type II: more than just fatty acids. J. Biol. Chem. 284, 9011-9015 (2009).
6. Jenni, S. et al. Structure of fungal fatty acid synthase and implications for iterative substrate shuttling. Science 316, 254-261 (2007).
7. Weiss, L. et al. Fatty-acid biosynthesis in man, a pathway of minor importance. Purification, optimal assay conditions, and organ distribution of fatty-acid synthase. Biol. Chem. Hoppe Seyler 367, 905-912 (1986).
8. Kuhajda, F.P. et al. Fatty acid synthesis: a potential selective target for antineoplastic therapy. Proc. Natl. Acad. Sci. USA 91, 6379-6383 (1994).
9. McGarry, J.D. & Brown, N.F. The mitochondrial carnitine palmitoyltransferase system. From concept to molecular analysis. Eur. J. Biochem. 244, 1-14 (1997).
10. Wang, Y., Kuhajda, F.P., Sokoll, L.J. & Chan, D.W. Two-site ELISA for the quantitative determination of fatty acid synthase. Clin. Chim. Acta 304, 107-115 (2001).
11. Flavin, R., Peluso, S., Nguyen, P.L. & Loda, M. Fatty acid synthase as a potential therapeutic target in cancer. Future Oncol. 6, 551-562 (2010).
12. Kuhajda, F.P. Fatty acid synthase and cancer: new application of an old pathway. Cancer Res. 66, 5977-5980 (2006).
13. Vαzquez, M.J. et al. Discovery of GSK837149A, an inhibitor of human fatty acid synthase targeting the β-ketoacyl reductase reaction. FEBS J. 275, 1556-1567 (2008).
14. Turrado, C. et al. New synthetic inhibitors of fatty acid synthase with anticancer activity. J. Med. Chem. 55, 5013-5023 (2012).
15. Kley, J.T., Mack, J., Hamilton, B., Scheuerer, S. & Redemann, N. Discovery of BI 99179, a potent and selective inhibitor of type I fatty acid synthase with central exposure. Bioorg. Med. Chem. Lett. 21, 5924-5927 (2011).
16. Oslob, J.D. et al. Imidazopyridine-based fatty acid synthase inhibitors that show anti-HCV activity and in vivo target modulation. ACS Med. Chem. Lett. 4, 113-117 (2013).
17. Meanwell, N.A. Improving drug candidates by design: a focus on physicochemical properties as a means of improving compound disposition and safety. Chem. Res. Toxicol. 24, 1420-1456 (2011).
18. Hallman, J. et al. Benzimidazoles as fatty acid synthase inhibitors. World Intellectual Property Organization WO2011056635 (2011).
19. Chaudhari, A.M., Hallman, J., Laudeman, C., Musso, D.L. & Parrish, C.A. Azabenzimidazoles as fatty acid synthase inhibitors. World Intellectual Property Organization WO2011066211 (2011).
20. Adams, N.D. et al. Triazolones as fatty acid synthase inhibitors. World Intellectual Property Organization WO2011103546 (2011).
21. Adams, N.D. et al. Fatty acid synthase inhibitors. World Intellectual Property Organization WO2012037299 (2012).
22. Aquino, C.J., Heyer, D., Kiesow, T.J., Musso, D.L. & Parrish, C.A. Fatty acid synthase inhibitors. World Intellectual Property Organization WO2012037298 (2012).
23. Adams, N.D., Reif, A.J. & Wiggall, K. Pyrimidinone derivatives as fatty acid synthase inhibitors. World Intellectual Property Organization WO2012096928 (2012).
24. Joshi, A.K., Witkowski, A. & Smith, S. Mapping of functional interactions between domains of the animal fatty acid synthase by mutant complementation in vitro. Biochemistry 36, 2316-2322 (1997).
25. Dodds, P.F., Guzman, M.G.F., Chalberg, S.C., Anderson, G.J. & Kumarj, S. Acetoacetyl-CoA reductase activity of lactating bovine mammary fatty acid synthase. J. Biol. Chem. 256, 6282-6290 (1981).
26. Carlisle-Moore, L., Gordon, C.R., Machutta, C.A., Miller, W.T. & Tong, P.J. Substrate recognition by the human fatty-acid synthase. J. Biol. Chem. 280, 42612-42618 (2005).
27. Dutler, H. et al. Fatty acid synthetase from pig liver 2. Characterization of the enzyme complex with oxidoreductase activity for alicyclic ketones as a fatty acid synthetase. Eur. J. Biochem. 22, 213-217 (1971).
28. Cook, P.F. & Cleland, W.W. Enzyme Kinetics and Mechanism (Garland Science, New York, 2007).
29. Yonetani, T. & Theorell, H. Studies on liver alcohol dehydrogenase complexes. 3. Multiple inhibition kinetics in the presence of two competitive inhibitors. Arch. Biochem. Biophys. 106, 243-251 (1964).
30. Orita, H. et al. Selective inhibition of fatty acid synthase for lung cancer treatment. Clin. Cancer Res. 13, 7139-7145 (2007).
31. Pizer, E.S., Wood, F.D., Paternack, G.R. & Kuhajda, F.P. Fatty acid synthase (FAS): a target for cytotoxic antimetabolites in HL60 promyelocytic leukemia cells. Cancer Res. 56, 745-751 (1996).
32. Swinnen, J.V. et al. Fatty acid synthase drives the synthesis of phospholipids partitioning into detergent-resistant membrane microdomains. Biochem. Biophys. Res. Commun. 302, 898-903 (2003).
33. Henneberry, A.L., Wright, M.M. & McMaster, C.R. The major sites of cellular phospholipid synthesis and molecular determinants of fatty acid and lipid head group specificity. Mol. Biol. Cell 13, 3148-3161 (2002).
34. Maier, T., Leibundgut, M. & Ban, N. The crystal structure of a mammalian fatty acid synthase. Science 321, 1315-1322 (2008).
35. Denney, J.W. Stabilization of working reagent solutions containing NADH, NADPH, and/or enzymes, and the use of such stabilized reagents in enzyme or substrate assays. European Patent Office EP0009222 (1980).
36. Anderson, V.E. & Hammes, G.G. Stereochemistry of the reactions catalyzed by chicken liver fatty acid synthase. Biochemistry 23, 2088-2094 (1984).
37. Katiyar, S.S., Cleland, W.W. & Porter, J.W. Fatty acid synthetase: a steady state kinetic analysis of the reaction catalyzed by the enzyme from pigeon liver. J. Biol. Chem. 250, 2709-2717 (1975).
38. Cleland, W.W. Derivation of rate equations for multisite ping-pong mechanisms with ping-pong reactions at one or more sites. J. Biol. Chem. 248, 8353-8355 (1973).
39. Cairns, R.A., Harris, I.S. & Mak, T.W. Regulation of cancer cell metabolism. Nat. Rev. Cancer 11, 85-95 (2011).
40. Price, A.C., Zhang, Y.M., Rock, C.O. & White, S.M. Cofactor-induced conformational rearrangements establish a catalytically competent active site and a proton relay conduit in FabG. Structure 12, 417-428 (2004).
41. Gao, L. et al. Simultaneous quantification of malonyl-CoA and several other short-chain acyl-CoAs in animal tissues by ion-pairing reversed-phase HPLC/MS. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. 853, 303-313 (2007).
42. Otwinowski, Z. & Minor, W. Processing of X-ray diffraction data collected in oscillation mode. Methods Enzymol. 276, 307-326 (1997).
43. McCoy, A.J. et al. Phaser crystallographic software. J. Appl. Crystallogr. 40, 658-674 (2007).
44. Winn, M.D., Murshudov, G.N. & Papiz, M.Z. Macromolecular TLS refinement in REFMAC at moderate resolutions. Methods Enzymol. 374, 300-321 (2003).
45. Winn, M.D. et al. Overview of the CCP4 suite and current developments. Acta Crystallogr. D Biol. Crystallogr. 67, 235-242 (2011).
46. Emsley, P., Lohkamp, B., Scott, W.G. & Cowtan, K. Features and development of Coot. Acta Crystallogr. D Biol. Crystallogr. 66, 486-501 (2010).